Nonacog beta pegol (N9‐GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients

Abstract Background/Objective We report the first analysis of an extended half‐life recombinant factor IX, nonacog beta pegol (N9‐GP), in previously untreated patients (PUPs) and minimally treated patients with hemophilia B. Methods Paradigm 6 (Safety and Efficacy of Nonacog Beta Pegol [N9‐GP] in Pr...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Anthony K. Chan, Jayanthi Alamelu, Chris Barnes, Ampaiwan Chuansumrit, May‐Lill Garly, Rikke Medom Meldgaard, Guy Young
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Elsevier 2020-10-01
Seri Bilgileri:	Research and Practice in Thrombosis and Haemostasis
Konular:	factor IX hemophilia B nonacog beta pegol previously untreated patients prophylaxis recombinant proteins
Online Erişim:	https://doi.org/10.1002/rth2.12412
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Nonacog beta pegol (N9‐GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients

Benzer Materyaller